Table 3.
Clinicopathologic data of five EMPD patients with prostate cancer
| Case | Age (years)1 | Longest diameter of the skin lesion (cm) | Invasion | Serum PSA level (ng/mL) | CEA (μg/L) | Gleason score (biopsy) | Time to prostate cancer (years) | Outcome | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | 11 | Subcutaneous tissue | 166 | 52.4 | 3 + 3 | 6 | RP | 12 |
| 2 | 61 | 12 | Subcutaneous tissue | 101 | 1.2 | 3 + 3 | 11 | RP | 150 |
| 3 | 60 | 10 | Subcutaneous tissue | 89 | 20 | 3 + 4 | 3 | ADT | 60 |
| 4 | 65 | 7 | Dermis | 120 | 16 | 4 + 3 | 3 | ADT | 60 |
| 5 | 75 | 13 | Subcutaneous tissue | 38 | 22 | 4 + 3 | 8 | ADT | 120 |
EMPD, extramammary Paget’s disease; PSA, prostate-specific antigen; CEA, carcinoembryonic antigen; RP radical prostatectomy; ADT, androgen deprivation therapy.
1
At presentation with metastatic disease.